Opioid

New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty

Thursday, July 29, 2021 - 12:30pm

The results of the study, A Multimodal Pain Management Protocol Including Preoperative Cryoneurolysis for Total Knee Arthroplasty to Reduce Pain, Opioid Consumption, and Length of Stay, were published in Arthroplasty Today .

Key Points: 
  • The results of the study, A Multimodal Pain Management Protocol Including Preoperative Cryoneurolysis for Total Knee Arthroplasty to Reduce Pain, Opioid Consumption, and Length of Stay, were published in Arthroplasty Today .
  • This retrospective analysis utilized data from patients who underwent TKA by a single surgeon at one center.
  • Patients who received iovera before TKA were compared with a historical control group including patients who underwent TKA without iovera.
  • The primary outcome was opioid intake at various time points from hospital stay to 6 weeks after discharge.

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

Wednesday, July 28, 2021 - 9:05pm

"The findings from this study demonstrate the ability of ZYNRELEF to serve as the foundation of non-opioid multimodal analgesia.

Key Points: 
  • "The findings from this study demonstrate the ability of ZYNRELEF to serve as the foundation of non-opioid multimodal analgesia.
  • ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which:
    can increase the risk of a heart attack or stroke that can lead to death.
  • Of the 98% of patients who completed the TSQM-9, most patients were "very" or "extremely" satisfied with their MMA regimen.
  • ZYNRELEF plus acetaminophen and ibuprofen was well tolerated; safety results were similar between concurrent and alternating MMA cohorts.

Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA

Tuesday, July 27, 2021 - 1:30pm

A weekly dosage form would free people from daily trips to methadone clinics and support consistency of treatment, recovery and wellbeing.

Key Points: 
  • A weekly dosage form would free people from daily trips to methadone clinics and support consistency of treatment, recovery and wellbeing.
  • The FDAs decision to grant LYN-014 Fast Track designation speaks to their commitment to provide people living with OUD with new, innovative treatment options.
  • LYN-014, which was granted investigational new drug status in April, is set to begin a Phase 1 clinical trial this quarter.
  • LYN-014, Lyndras investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).

Health Canada Launches National Call for Proposals for the Substance Use and Addictions Program

Thursday, July 22, 2021 - 6:53pm

"Through Canada's Substance Use and Addictions Program and this call for proposals we are working with community-based organizations to provide much-needed support to those that need it, reducing harms and reducing deaths.

Key Points: 
  • "Through Canada's Substance Use and Addictions Program and this call for proposals we are working with community-based organizations to provide much-needed support to those that need it, reducing harms and reducing deaths.
  • Since SUAP was established in 2016, there have been 2 national calls for proposals (2017, 2019).
  • These national calls for proposals, along with other targeted investments, have resulted in over 200 projects across Canada worth over $360 million.
  • Tragically, the latest national data indicates that 2020 was the worst year for opioid-related deaths since the Public Health Agency of Canada (PHAC) began monitoring the crisis in 2016.

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

Thursday, July 22, 2021 - 1:30pm

Non-alcoholic steatohepatitis (NASH) is also being explored.In addition, POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER platform technology,is now FDA-approved.

Key Points: 
  • Non-alcoholic steatohepatitis (NASH) is also being explored.In addition, POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER platform technology,is now FDA-approved.
  • For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp .
  • Further information regarding these and other risks is included in DURECT's Form 10-K filed on March 5, 2021 under the heading "Risk Factors."
  • Full prescribing information for POSIMIR, including its Boxed Warning, can be found at www.posimir.com .

BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021

Thursday, July 22, 2021 - 1:00pm

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.

Key Points: 
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
  • BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
  • 2021BioDelivery Sciences International, Inc. All rights reserved.

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

Tuesday, July 20, 2021 - 10:00pm

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain. Q-State will subsequently be eligible for an additional $1 million in grant funding based on successful completion of certain program milestones.

Key Points: 
  • Funded as part of the NIH HEAL InitiativeSM, the grant supports Q-States efforts to pursue analgesic treatment paradigms beyond those associated with opioids.
  • The company is currently advancing ASO candidates targeting Nav1.7, Nav1.8, or both channels using the companys AI-enabled computational neuroscience technology.
  • In addition to cancer pain, these ASO candidates also have potential applicability in the treatment of a variety of other moderate-to-severe pain states.
  • This grant was awarded by the National Institute of Cancer of the National Institutes of Health under Award Number R44CA247110.

Focusing on Solutions to the Opioid Crisis, Foundation for Opioid Response Efforts (FORE) Announces Family- and Community-Based Initiatives to Prevent Substance Use Disorder and Overdose

Tuesday, July 20, 2021 - 4:00pm

These children are at greater risk of themselves developing a substance use disorder later in life.

Key Points: 
  • These children are at greater risk of themselves developing a substance use disorder later in life.
  • The Foundation for Opioid Response Efforts (FORE) was founded in 2018 as a private 501(c)(3) national, grant-making foundation focused on addressing the nations opioid crisis.
  • FORE is committed to funding a diversity of projects contributing solutions to the crisis at national, state, and community levels.
  • FOREs mission is to support partners advancing patient-centered, innovative, evidence-based solutions impacting people experiencing opioid use disorder, their families, and their communities.

Addiction Treatment Innovator and Advocate Dr. Marvin Seppala to Retire as Hazelden Betty Ford’s Chief Medical Officer

Wednesday, July 14, 2021 - 7:30pm

Marvin D. Seppala, MD, a nationally known psychiatrist and addiction treatment leader who pioneered a new, integrated approach to treating opioid addiction and inspired others with his own story of recovery, will retire as chief medical officer of the Hazelden Betty Ford Foundation at the end of 2021.

Key Points: 
  • Marvin D. Seppala, MD, a nationally known psychiatrist and addiction treatment leader who pioneered a new, integrated approach to treating opioid addiction and inspired others with his own story of recovery, will retire as chief medical officer of the Hazelden Betty Ford Foundation at the end of 2021.
  • Dr. Seppala, who grew up in southern Minnesota and now lives near Portland, Ore., has been Hazelden Betty Fords chief doctor for most of the past 25 years, with two brief stints of work elsewhere during that time.
  • Foremost among Dr. Seppalas many achievements has been the development, implementation and study of Hazelden Betty Fords Comprehensive Opioid Response with the Twelve Steps (COR-12).
  • The author of several books on addiction treatment, opioids and pain, Dr. Seppala also served as a board member of the American Society of Addiction Medicine for several years.

National Safety Council Statement on New CDC Drug Overdose Data

Thursday, July 15, 2021 - 2:24am

ITASCA, Ill., July 14, 2021 /PRNewswire/ --The National Safety Council is greatly disappointed by the latest provisional drug overdose data released by the CDC.

Key Points: 
  • ITASCA, Ill., July 14, 2021 /PRNewswire/ --The National Safety Council is greatly disappointed by the latest provisional drug overdose data released by the CDC.
  • Opioids are the cause of the single worst drug overdose crisis in U.S. history, and the coronavirus pandemic has only exacerbated this epidemic.
  • We call for the confirmation of an Office of National Drug Control Policy leader as soon as possible.
  • The National Safety Council is America's leading nonprofit safety advocate and has been for over 100 years.